32 results about "Enzyme family" patented technology

The invention discloses a miniaturization cucumber plant associated protein and a coding gene thereof and an application thereof. An amino acid sequence of the protein is shown as a sequence table 2, which belongs to AAA ATP enzyme family, and is related with microtubule associated protein; the coding gene of the protein has a base sequence shown as a sequence table 1, if the mutation is generated on the base sequence, such as cytosine (C) with 1058 bp bit is substituted by thymidine (T), serine (Ser) with 353 bit for coding the protein is changed to phenylalanine (Phe), the protein inhibits the normal growth of the microtubule cell, the microtubule cytoskeleton is lost, the arrangement is abnormal, concretely, the plant phenotype is plant miniaturization, the height of the mutant plant is about 20% of the height of a normal wild type plant, the fruit length is about 10% of the length of normal wild type fruit, and the leaves and the seeds are obviously shortened. The application of the protein and the coding gene can create condition for cucumber strain-type improvement and cross breeding or exploitation of transgene plants.

The present invention is directed to the discovery of a novel family of enzymes designated herein as mRNA interferases that exhibit endoribonuclease activity. The novel finding of the present inventors, therefore, presents new applications for which mRNA interferase nucleic and amino acid sequences, and compositions thereof may be used to advantage. The invention also encompasses screening methods to identify compounds/agents capable of modulating mRNA interferase activity and methods for using such compounds/agents. Also provided is a kit comprising mRNA interferase nucleic and/or amino acid sequences, mRNA interferase activity compatible buffers, and instruction materials.

A gene umcel5A coding cellulase features that it contains the nucleoside sequence shown by SEQ ID No.2 or its homologous sequences. The cellulase coded by said gene and its application in degradating cellulose are also disclosed.

The invention is relative to the various uses of a novel enzyme family, referred to as THYX, capable of catalyzing the synthesis of thymidine 5'-monophosphate in the absence of an active thymidylate synthase enzyme (ThyA). The invention also relates to reaction media for the thymidylate synthase activity of a THYX polypeptide as well as screening methods implementing said reaction media, as well as kits for implementing such methods.

The invention relates to a saccharase gene of a coding sugar-based hydrolytic ferment family 32 and applications thereof. The invention is characterized by comprising a nucleotide sequence of SEQ ID NO: 1 and or a functional-equivalent variant thereof. The invention comprises the saccharase (SEQ ID NO:2) of the gene or the functional-equivalent variant code thereof and the applications of the saccharase in degrading cane sugar.

The present invention is directed to the discovery of a novel family of enzymes designated herein as mRNA interferases that exhibit endoribonuclease activity. The novel finding of the present inventors, therefore, presents new applications for which mRNA interferase nucleic and amino acid sequences, and compositions thereof may be used to advantage. The invention also encompasses screening methods to identify compounds/agents capable of modulating mRNA interferase activity and methods for using such compounds/agents. Also provided is a kit comprising mRNA interferase nucleic and/or amino acid sequences, mRNA interferase activity compatible buffers, and instruction materials.

The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3α ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products.

The invention discloses combined use of a tetravalent cisplatin predrug and a biological reducing drug. The structural f formula of the tetravalent cisplatin predrug is represented by a formula (I) (shown in description), wherein m represents 0-1000, n represents 1-1000, and I represents 1-1000. The tetravalent cisplatin predrug is loaded with a biological reducing drug, namely tirapazamine, a cisplatin anti-cancer drug is released through degradation in a tumor microelement,and the high expression of enzyme families of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (NOX) in cancer cells can be induced, so that the oxygen consumption rate of the cancer cells is increased, the pesticide effect of the biological reducing drug, namely tirapazamine is further improved, and the treatment effect of the whole cancer treatment process can be improved through synergistic treatment.

It is an aim of the present invention to provide inhibitors of human diphtheria toxin-like ADP-ribosyltransferases, such as ARTD10, for use as a medicine. It is another aim of the invention to provide compounds for use as human mono-ADP-ribosyltransferase (mARTD) inhibitors in vitro. In the present invention, it has been discovered that human ARTD10, which belongs to an enzyme family linked to cancer biology, can be specifically inhibited by the benzamide comprising compounds disclosed in the invention, such as 4,4′-oxydibenzamide.

The invention provides esterases and a coding gene and an application thereof, and belongs to the technical field of genetic engineering and enzyme engineering. A gene for coding the esterases E31-4922 is obtained through screening and cloning from Antarctic soil; through researching expression proteins of the esterases, the inventor finds that the esterases show high degradation activity on short-chain esters, the optimum pH is 7.5, and the esterases stably exist in the pH range being 7.0-8.0; the optimum enzyme activity temperature is 80 DEG C, and the esterases maintain vitality being overthan 80% in the range of 60-90 DEG C; the esterases are thermally-stable esterases, and show higher tolerance for high temperature environment being over than 60 DEG C; and the esterases have important significance in enriching the family members of the esterases particularly the family members of high temperature resistant esterases.

The present invention includes novel derivatives, analogs, and intermediates of the natural products radicicol, pochonins, pochoximes, and their syntheses. The present invention also provides a pharamceutical composition comprising the present compound and the use of the compound as inhibitors of kinases and of the enzyme family known as heat shock protein 90 (HSP90).

The invention discloses an application of glutathione mercaptotransferase as a detoxifying enzyme for preventing and treating duck liver injury caused by AFB1, and provides an application of GST and GST3 as target enzymes for preventing and treating animal liver injury caused by AFB1 by testing 10 GST in a duck GSTs enzyme family and screening out GST and GST3 with detoxifying effects. The glutathione mercaptotransferase (GST or GST3) provided by the invention can effectively inhibit or relieve AFB1-induced liver toxicity of ducklings, and is mainly related to the metabolism of catalyzing AFBO to generate nontoxic AFBO-GSH. The GST and the GST3 can be used as drugs for treating duck liver injury caused by AFB1 and provide new target genes for development of novel feed additives.

Provided are certain glycosyl hydrolase family 3 (GH3) beta-xylosidases engineered to acquire beta-glucosidase activities. Provided also are compositions comprising such multi-functional GH3 enzymes and methods of use or industrial applications thereof.

The invention provides isolated nucleic acids molecules, designated 25501 nucleic acid molecules, which encode novel transferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 25501 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 25501 gene has been introduced or disrupted. The invention still further provides isolated 25501 proteins, fusion proteins, antigenic peptides and anti-25501 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

The invention relates to the technical field of biology, in particular to a tyrosine phosphatase substrate identification method. The tyrosine phosphatase substrate identification method provided by the invention comprises the following steps: placing a system comprising a potential substrate interacting with tyrosine phosphatase in the presence of tyrosine phosphatase-PafA fusion protein and pup protein, and marking the pup protein; and enriching a potential substrate interacting with tyrosine phosphatase through labeled pup protein, wherein the tyrosine phosphatase-PafA fusion protein comprises a tyrosine phosphatase fragment and a PafA fragment, and the tyrosine phosphatase fragment has a substrate capture mutant. The tyrosine phosphatase substrate identification method and system provided by the invention can promote biological research on tyrosine phosphatase to any important tyrosine phosphatase family member, and have good industrialization prospects.